## Chronic Rhinosinusitis Treatment: Clarifying the Options Beyond Surgery
The persistent discomfort of chronic rhinosinusitis (CRS) affects millions globally, often leading individuals to seek relief through various avenues, including antibiotics and surgical intervention. Recent research, culminating in the landmark MACRO trial published in The Lancet in November 2025, is reshaping our understanding of effective treatment strategies. This article delves into the findings of the MACRO trial, comparing the clinical effectiveness of clarithromycin to endoscopic sinus surgery (ESS) for adults grappling with CRS, both with and without nasal polyps, and provides a thorough overview of navigating this complex condition. As of November 24, 2025, the medical community is actively discussing the implications of these findings for patient care.
Did You Know? Approximately 1 in 7 adults in the United States experience chronic sinusitis, impacting their quality of life and contributing to important healthcare costs.
Understanding Chronic Rhinosinusitis: symptoms and diagnosis
Chronic rhinosinusitis is defined as inflammation of the paranasal sinuses lasting for 12 weeks or longer, despite attempts at medical management. Symptoms can range from facial pain and pressure to nasal congestion, loss of smell, and postnasal drip. The presence of nasal polyps – soft, painless growths in the nasal passages – further complicates the clinical picture. Accurate diagnosis is crucial,typically involving a detailed medical history,physical examination,and possibly imaging studies like CT scans to assess the extent of sinus inflammation. The American Academy of Otolaryngology – Head and Neck Surgery provides detailed guidelines for diagnosis and management, updated regularly to reflect the latest evidence. [https://www.entnet.org/](https://www.entnet.org/)
Pro Tip: keep a symptom diary to track the severity and frequency of your symptoms. This information can be invaluable when discussing treatment options with your doctor.
The Role of antibiotics in CRS Management
Traditionally,antibiotics have been a mainstay in treating CRS,aiming to eradicate bacterial infections contributing to the inflammation. However, increasing antibiotic resistance and concerns about their long-term effects have prompted a reevaluation of their role. The MACRO trial specifically investigated the efficacy of clarithromycin, a macrolide antibiotic, as a potential alternative to more aggressive interventions. A 2024 report by the CDC highlighted a continued rise in antibiotic-resistant bacteria, emphasizing the need for judicious antibiotic use. [https://www.cdc.gov/antibiotic-resistance/](https://www.cdc.gov/antibiotic-resistance/)
The MACRO Trial: A Paradigm Shift in CRS Treatment?
the MACRO (MACrolide versus Endoscopic sinus Surgery) trial, a pragmatic, multicentre, three-arm, randomised, placebo-controlled phase 4 trial, represents a significant advancement in our understanding of CRS treatment. Conducted across multiple clinical sites,the study enrolled a significant cohort of adults diagnosed with CRS,with and without nasal polyps.Participants were randomly assigned to one of three groups: clarithromycin,endoscopic sinus surgery,or placebo. The primary outcome measure was the change in Sino-Nasal outcome Test-22 (SNOT-22) scores – a validated questionnaire assessing the impact of CRS on quality of life – at 12 months. The trial, initially published in November 2025, included an updated appendix on November 20, 2025, acknowledging the wider team involved in the research.
The results revealed a surprising finding: clarithromycin demonstrated comparable effectiveness to endoscopic sinus surgery in improving SNOT-22 scores for patients *without* nasal polyps. However, for individuals *with* nasal polyps, surgery proved more effective. This suggests a personalized approach to CRS treatment is paramount, tailoring interventions based on the presence or absence of polyps. This aligns with emerging trends in precision medicine,where treatment strategies are customized to individual patient characteristics.
Here’s a summary of the key findings:
| Treatment Group | CRS Without Polyps | CRS With Polyps |
|---|---|---|
| Clarithromycin | Comparable to ESS | less Effective than ESS
|